Table 2.
Analysis of changes in disease activity parameters at follow-up visits.
| Parameter | Baseline (Week 0) | 1st Follow-Up (Week 6) |
2nd Follow-Up (Week 12) |
p-Value (2nd Follow-Up vs. Week 0) |
|---|---|---|---|---|
| Entire studied population (n = 48) | ||||
| Fecal calprotectin level (µg/g) | 1045.00 (IQR = 1188.00) | 633.50 (IQR = 1268.00) | 363.00 (IQR = 665.00) | 0.0002 |
| PCDAI (pt) | 12.50 (IQR = 17.50) | 5.00 (IQR = 7.5) | 5.00 (IQR = 7.50) | 0.0002 |
| CRP (mg/dL) | 1.00 (IQR = 1.78) | 0.20 (IQR = 0.42) | 0.19(IQR = 0.25) | 0.0002 |
| ESR (mm/h) | 21.00 (IQR = 19.50) | 10.00 (IQR = 13.00) | 11.00 (IQR = 11.00) | 0.0014 |
| Population of patients who were not in clinical remission at baseline, PCDAI ≥ 10 (n = 29) | ||||
| Fecal calprotectin level (µg/g) | 1410.00 (IQR = 1839.00) | 655.00 (IQR = 1919.50) | 567.00 (IQR = 1147.50) | 0.0106 |
| PCDAI (pt) | 20.00 (IQR = 7.50) | 7.50 (IQR = 5.00) | 5.00 (IQR = 5.00) | 0.0002 |
| Population of patients who were in clinical remission at baseline, PCDAI < 10 (n = 18) | ||||
| Fecal calprotectin level (µg/g) | 939.50 (IQR = 989.00) | 587.50 (IQR = 1433.50) | 133.00 (IQR = 284.50) | 0.0132 |
Results expressed as a median. IQR—interquartile range.